Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. (Q54377548)

29 May 2018

title

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. (English)

1 reference

29 May 2018

1 reference

1 reference

6

1 reference

29 May 2018

author name string

Geert J L H van Leenders

1

1 reference

29 May 2018

Joost L Boormans

2

1 reference

29 May 2018

Cornelis J Vissers

3

1 reference

29 May 2018

A Marije Hoogland

4

1 reference

29 May 2018

Anke A J W M Bressers

5

1 reference

29 May 2018

Jan Trapman

7

1 reference

29 May 2018

publication date

15 April 2011

1 reference

29 May 2018

published in

Modern Pathology

1 reference

29 May 2018

volume

24

1 reference

29 May 2018

issue

8

1 reference

29 May 2018

page(s)

1128-1138

1 reference

29 May 2018

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.65

exact match

0 references

cites work

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

ETS gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Recurrent gene fusions in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

The role of SPINK1 in ETS rearrangement-negative prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Morphological features of TMPRSS2-ERG gene fusion prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Antibody-based detection of ERG rearrangement-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Expression and diagnostic utility of alpha-methylacyl-CoA-racemase (P504S) in foamy gland and pseudohyperplastic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Expression of basal cell keratins in human prostate cancer metastases and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Integrative molecular concept modeling of prostate cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Complex patterns of ETS gene alteration arise during cancer development in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

inferred from DOI database lookup

7 January 2021

based on heuristic

False-negative Prostate Needle Biopsies: Frequency, Histopathologic Features, and Follow-up

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

inferred from DOI database lookup

7 January 2021

based on heuristic

P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.65

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.2011.65

1 reference

29 May 2018

PubMed ID

21499236

1 reference

29 May 2018